HSP90 Inhibitors Blocking Multiple Oncogenic Signaling Pathways for the Treatment of Cancer

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Heat Shock Proteins

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/978-3-030-03952-3_20
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function.

  2017cited by this paper
• Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.

  2017cited by this paper
• First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors.

  2017cited by this paper
• 1479PDPhase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refractory to imatinib, sunitinib and regorafenib

  2017cited by this paper
• Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.

  2017cited by this paper
• Resorcinol-Based Grp94-Selective Inhibitors.

  2017cited by this paper
• Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.

  2017cited by this paper
• Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors.

  2017cited by this paper
• New dihydropyrimidin-2(1H)-one based Hsp90 C-terminal inhibitors

  2016cited by this paper
• Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.

  2016cited by this paper
• Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

  2016cited by this paper
• Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.

  2016cited by this paper
• Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors.

  2016cited by this paper
• Hsp90: Friends, clients and natural foes.

  2016cited by this paper
• A Human Variant of Glucose-Regulated Protein 94 That Inefficiently Supports IGF Production.

  2016cited by this paper
• Identification of the key structural elements of a dihydropyrimidinone core driving toward more potent Hsp90 C-terminal inhibitors.

  2016cited by this paper
• Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future.

  2016cited by this paper
• Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.

  2016cited by this paper
• Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.

  2015cited by this paper
• Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90

  2015cited by this paper
• Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

  2015cited by this paper
• Endoplasmic reticulum heat shock protein gp96 maintains liver homeostasis and promotes hepatocellular carcinogenesis.

  2015cited by this paper
• Expression of heat-shock protein gp96 in gallbladder cancer and its prognostic clinical significance.

  2015cited by this paper
• Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1.

  2015cited by this paper
• KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells

  2015cited by this paper
• A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease

  2015cited by this paper
• Blockage of Conformational Changes of Heat Shock Protein gp96 on Cell Membrane by a α-Helix Peptide Inhibits HER2 Dimerization and Signaling in Breast Cancer

  2015cited by this paper
• Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies

  2015cited by this paper
• Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90

  2015cited by this paper
• High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma

  2015cited by this paper
• Ring-truncated deguelin derivatives as potent Hypoxia Inducible Factor-1α (HIF-1α) inhibitors.

  2015cited by this paper
• Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.

  2015cited by this paper
• Targeting the Hsp90 C-terminal domain by the chemically accessible dihydropyrimidinone scaffold.

  2015cited by this paper
• Cell membrane gp96 facilitates HER2 dimerization and serves as a novel target in breast cancer

  2015cited by this paper
• Abstract B87: First-in-human phase I dose escalation study of TAS-116, a novel, orally active HSP90α and HSP90β selective inhibitor, in patients with advanced solid tumors

  2015cited by this paper
• Discovery and identification of Cdc37-derived peptides targeting the Hsp90–Cdc37 protein–protein interaction

  2015cited by this paper
• Mitochondrial Hsp90s suppress calcium-mediated stress signals propagating from mitochondria to the ER in cancer cells

  2014cited by this paper
• Suppression of tumor necrosis factor receptor‐associated protein 1 expression induces inhibition of cell proliferation and tumor growth in human esophageal cancer cells

  2014cited by this paper
• Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.

  2014cited by this paper
• TRAP1 Regulates Proliferation, Mitochondrial Function, and Has Prognostic Significance in NSCLC

  2014cited by this paper
• Identifying a C-terminal ATP binding sites-based novel Hsp90-Inhibitor in silico: a plausible therapeutic approach in Alzheimer's disease.

  2014cited by this paper
• Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim

  2014cited by this paper
• Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease.

  2014cited by this paper
• TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells.

  2014cited by this paper
• TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models

  2014cited by this paper
• Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

  2014cited by this paper
• Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.

  2014cited by this paper
• Towards the discovery of drug-like epigallocatechin gallate analogs as Hsp90 inhibitors.

  2014cited by this paper
• Molecular Cochaperones: Tumor Growth and Cancer Treatment

  2013cited by this paper
• Hsp90, an unlikely ally in the war on cancer

  2013cited by this paper
• Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2.

  2013cited by this paper
• Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1

  2013cited by this paper
• Molecular Mechanisms of Silibinin-Mediated Cancer Chemoprevention with Major Emphasis on Prostate Cancer

  2013cited by this paper
• Molecular Chaperone gp96 Is a Novel Therapeutic Target of Multiple Myeloma

  2013cited by this paper
• Inhibition of HSP90 molecular chaperones: moving into the clinic.

  2013cited by this paper
• Essential roles of grp94 in gut homeostasis via chaperoning canonical Wnt pathway

  2013cited by this paper
• α7 Helix Region of αI Domain Is Crucial for Integrin Binding to Endoplasmic Reticulum Chaperone gp96

  2013cited by this paper
• Overexpression of GRP94 in breast cancer cells resistant to oxidative stress promotes high levels of cancer cell proliferation and migration: implications for tumor recurrence.

  2012cited by this paper
• The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase

  2012cited by this paper
• 291 TAS-116, a Novel, Orally Bioavailable HSP90a/β Selective Inhibitor Demonstrates Highly Potent Antitumor Activity in Preclinical Models with a Favorable PK Profile

  2012cited by this paper
• Development of a Grp94 inhibitor.

  2012cited by this paper
• Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.

  2012cited by this paper
• The therapeutic target Hsp90 and cancer hallmarks.

  2012cited by this paper
• Insulin-like growth factor: current concepts and new developments in cancer therapy.

  2012cited by this paper
• Deletion of muscle GRP94 impairs both muscle and body growth by inhibiting local IGF production

  2012cited by this paper
• A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells.

  2011cited by this paper
• Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease

  2011cited by this paper
• Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer.

  2011cited by this paper
• Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells.

  2011cited by this paper
• Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase‐3 β/β‐catenin pathway

  2011cited by this paper
• Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications.

  2011cited by this paper
• Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

  2011cited by this paper
• Identification and initial SAR of silybin: an Hsp90 inhibitor.

  2011cited by this paper
• Integrins in cancer: biological implications and therapeutic opportunities

  2010cited by this paper
• A study of high‐dose oral silybin‐phytosome followed by prostatectomy in patients with localized prostate cancer

  2010cited by this paper
• Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma

  2010cited by this paper
• Targeting the dynamic HSP90 complex in cancer

  2010cited by this paper
• Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer.

  2010cited by this paper
• Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study

  2010cited by this paper
• Synergistic action of the novel HSP90 inhibitor NVP‐AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

  2010cited by this paper
• Heat shock protein 90: inhibitors in clinical trials.

  2010cited by this paper
• Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy.

  2010cited by this paper
• Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo

  2010cited by this paper
• Preclinical Characterization of Mitochondria-Targeted Small Molecule Hsp90 Inhibitors, Gamitrinibs, in Advanced Prostate Cancer

  2010cited by this paper
• TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells.

  2009cited by this paper
• Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol.

  2009cited by this paper
• The Human Cdc37·Hsp90 Complex Studied by Heteronuclear NMR Spectroscopy*

  2009cited by this paper
• KU135, a Novel Novobiocin-Derived C-Terminal Inhibitor of the 90-kDa Heat Shock Protein, Exerts Potent Antiproliferative Effects in Human Leukemic Cells

  2009cited by this paper
• (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor.

  2009cited by this paper
• The chaperone activity of GRP94 toward insulin-like growth factor II is necessary for the stress response to serum deprivation.

  2009cited by this paper
• (-)-Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line Mia Paca-2.

  2009cited by this paper
• Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design.

  2009cited by this paper
• Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90.

  2009cited by this paper
• Deguelin inhibits human hepatocellular carcinoma by antiangiogenesis and apoptosis.

  2008cited by this paper
• Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma

  2008cited by this paper
• Synthesis and evaluation of derrubone and select analogues.

  2008cited by this paper
• IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells

  2008cited by this paper
• Derrubone, an inhibitor of the Hsp90 protein folding machinery.

  2007cited by this paper
• Structural basis for depletion of heat shock protein 90 client proteins by deguelin.

  2007cited by this paper
• Chemopreventive Efficacy of Silymarin in Skin and Prostate Cancer

  2007cited by this paper

• LaSOM 335, active against bladder cancer cells, interferes with Let‐60 (hRas) and reduces CD73 expression/activity

  2023cites this paper